

A Review of Pharmacology and Toxicity of Stomachic Mixture Constituents

Nattawut Leelakanok¹, Naphatson Chanthathamrongsiri², Worathat Thitikornpong³

¹Department of Clinical Pharmacy, Faculty of Pharmaceutical Sciences, Burapha University

²Department of Pharmacognosy and Medicinal Chemistry, Faculty of Pharmaceutical Sciences, Burapha University

³Department of Food and Pharmaceutical Chemistry, Faculty of Pharmaceutical Sciences, Chulalongkorn University

Abstract

Stomachic mixture is used widely for the treatment of gastrointestinal conditions. However, the evidence for its efficacy and safety is scarce. The review of pharmacology and toxicity of stomachic mixture constituents provides information for patients and healthcare providers in making decision to use this drug. Stomachic mixture products registered in Thailand as shown in the Thai Food and Drug Administration database in 2018 contained sodium bicarbonate as the main active ingredient of the stomachic mixture. The herbal components in the stomachic recipe registered to Thai FDA were volatile oils, anthraquinone glycosides, bitter substances, and spicy substances. The amount of each ingredient in the stomachic mixture, when the mixture was used as recommended, was lower than toxic doses of the component. However, the sodium amount in the stomachic mixture could be high for patients requiring sodium restriction. Data regarding the use of stomachic mixture in pregnant and lactating women were insufficient. Therefore, the stomachic mixture should be avoided in patients requiring sodium restriction, pregnant women, and breastfeeding women. Side effects of stomachic mixture on the liver, kidney, heart, gastrointestinal tract, and central nervous system and hypoglycemia are possible.

Keywords: mixture stomachica, stomachic mixture, sodium bicarbonate, thai traditional medicine

Received: May 14, 2020, **Revised manuscript received:** Jun 27, 2020, **Accepted:** Jun 30, 2020

Correspondence: Nattawut Leelakanok, Department of Clinical Pharmacy, Faculty of Pharmaceutical Sciences, Burapha University, Mueang, Chonburi 20131 **E-mail:** nattawut.le@go.buu.ac.th

การทบทวนวรรณกรรมเภสัชวิทยาและพิชวิทยาของส่วนประกอบในยาธาตุน้ำแดง

ณัฐวุฒิ ลีลาภานก¹, นภัสสร จันทร์ธำรงศิริ², วรชัย รัฐิติกรพงศ์³

¹สาขาวิชาเภสัชกรรมปฏิบัติและการบริบาล คณะเภสัชศาสตร์ มหาวิทยาลัยบูรพา

²สาขาวิชาเภสัชเวทและเภสัชเคมี คณะเภสัชศาสตร์ มหาวิทยาลัยบูรพา

³ภาควิชาอาหารและเภสัชเคมี คณะเภสัชศาสตร์ จุฬาลงกรณ์มหาวิทยาลัย

บทคัดย่อ

ยาธาตุน้ำแดงเป็นยาที่ใช้อย่างแพร่หลายสำหรับรักษาอาการในระบบทางเดินอาหาร อย่างไรก็ตามไม่มีงานศึกษา รองรับประสิทธิภาพและความปลอดภัยของยาธาตุน้ำแดง การทบทวนวรรณกรรมเภสัชวิทยาและพิชวิทยาของส่วนประกอบในยาธาตุน้ำแดงจะช่วยเพิ่มข้อมูลแก่ผู้ป่วยและบุคลากรสาธารณสุขประกอบการตัดสินใจใช้ยา จากสูตรตำรับยาธาตุน้ำแดงที่ขึ้นทะเบียนในประเทศไทยซึ่งแสดงไว้ในฐานข้อมูลของสำนักงานคณะกรรมการอาหารและยาในปี 2561 พบว่า ส่วนประกอบหลักของยาธาตุน้ำแดงคือโซเดียมและไบคาร์บอเนต สำหรับส่วนประกอบสมุนไพรในตำรับยาธาตุน้ำแดงซึ่งได้รับการขึ้นทะเบียนในประเทศไทย ประกอบด้วย น้ำมันหอมระเหย แอนทราควิโนน ไกลโคไซด์ สารที่มีรสขม และสารที่มีรสเผ็ด เมื่อรับประทานยาธาตุน้ำแดงตามขนาดยาที่แนะนำ ร่างกายจะได้รับส่วนประกอบเหล่านี้ในปริมาณต่ำกว่าขนาดที่ทำให้เกิดพิษ อย่างไรก็ตาม ปริมาณโซเดียมในยาธาตุน้ำแดงอาจมากเกินไปสำหรับผู้ป่วยที่ต้องจำกัดโซเดียม อีกทั้งยังมีข้อมูลการใช้ยาธาตุน้ำแดงในสตรีมีครรภ์และให้นมบุตรไม่เพียงพอ จึงไม่ควรใช้ยาธาตุน้ำแดงในผู้ป่วยที่ต้องจำกัดปริมาณโซเดียม สตรีมีครรภ์และให้นมบุตร และยาธาตุน้ำแดงอาจมีผลข้างเคียงต่อตับ ไต หัวใจ ทางเดินอาหาร และระบบประสาทส่วนกลาง รวมถึงอาจก่อให้เกิดภาวะน้ำตาลในเลือดต่ำได้

คำสำคัญ: ยาธาตุน้ำแดง โซเดียม ไบคาร์บอเนต ยาแผนไทย

Introduction

Traditional medicine is well established in Europe, Asia, Africa, and Arabian countries. In Asia, traditional Chinese medicine and Ayurvedic medicine influence traditional medicine in many countries including Thailand (1). Mixture stomachica or stomachic mixture is a recipe of an over the counter antacid and carminative (2) that was used widely in Thailand. The main active ingredients, except for sodium bicarbonate, are raw herb materials or herbal preparations. Although mixture stomachica is very popular and used frequently in Thailand, the evidence supporting its efficacy and safety is scarce. This review summarizes evidence of

pharmacological effects and potential toxicities of the components of mixture stomachica which helps understand the pharmacology and toxicity of this recipe.

Approved products in Thailand

Until 2018, there were 31 formulations of stomachic mixture approved by Thai Food and Drug Administration (Thai FDA) (3). Only 17 approved formulations had information available in the Thai FDA database. The available information for the formulations is demonstrated in Table 1. The amount of peppermint oil in the peppermint spirit and camphor in camphor water was calculated using a 0.1 multiplicative factor

based on the requirement that the peppermint spirit and camphor water must contain not less than 0.9 ml and not more than 11 ml of peppermint oil, and not less than 0.9 mg and not more than 11 mg of camphor, respectively (4). From the review of the Thai FDA database, the common components of mixture stomachica were sodium bicarbonate, rhubarb (either as a powder or extract), peppermint oil, and ethanol. Minor ingredients were cardamom, Tinospora, camphor, gentian, aromatic ammonia, and ginger. All the minor constituents were either hydroalcohol extracted or alcoholic extracted. A trace amount of methanol (1.60±0.39 µl/ml) could be found in some formulations (5). The suggested dosing of the registered products was a tablespoonful (15 ml) before a meal, three times a day.

Component of approved stomachic mixture

Sodium bicarbonate

Sodium bicarbonate is widely used as a home remedy for indigestion. It reacts with hydrochloric acid in the stomach as followed: $\text{NaHCO}_3 + \text{HCl} \rightarrow \text{NaCl} + \text{H}_2\text{O} + \text{CO}_2$. Sodium bicarbonate is an effective antacid

with short action. However, it is not used as the first-line antacid because it has the lowest power in the acid-neutralizing capacity test ($7.40 \pm 0.12 \text{ mEq}$) among the inorganic antacids (6). Its reaction with hydrochloric acid results in carbon dioxide which can cause belching (7). Gas release induced by the ingestion of one-half teaspoon of sodium bicarbonate could be a major cause of gastric rupture (8). Metabolic alkalosis is also possible from chronic ingestion (9). However, the ingestion of sodium bicarbonate is generally safe. Sodium bicarbonate ingestion up to 150 mg/kg for 10 days was safe (10). Nevertheless, stomachic mixture contains 8.8 mg/ml of sodium and, therefore, should be avoided in those requiring sodium restriction such as stroke patients for which less than 1500 mg/day of sodium is allowed (Table 2) (11). World Health Organization (WHO) recommended sodium consumption of fewer than two grams per day to reduce the risk of hypertension (12). With the average consumption of approximately four grams of sodium per day in Thai people (13), the consumption of any amount of stomachic mixture should be avoided.

Table 1. Compositions of the stomachic mixture formulations as appeared in the Thai FDA database in 2018.

composition	number of formulations (total = 17)	quantity ¹	units
sodium bicarbonate	17	32.0 (18.0, 40.0)	mg/ml
compound rhubarb tincture	14	106.7 (16.7, 106.7)	µl/ml
peppermint oil	8 (6) ²	2.0 (0.9, 2.0)	µl/ml
compound cardamom tincture	4	33.3 (33.3, 33.3)	µl/ml
camphor	3 (1) ³	2.0 (0.8, 9.0)	mg/ml
compound tinospora tincture	3	33.3 (33.3, 33.3)	µl/ml
ginger tincture	3	53.3 (13.3, 66.7)	µl/ml
compound gentian tincture	2	38.3 (10.0, 66.7)	µl/ml
aromatic ammonia spirit	1	8.3 (8.3, 8.3)	µl/ml
ippecacuanha tincture	1	0.02 (0.02, 0.02)	ml/ml
rhubarb powder	1	75.0 (75.0, 75.0)	mg

1: Reported as median (minimum, maximum) and calculated from the formulations containing the composition.

2: The number of formulations containing peppermint spirit is shown in parenthesis.

3: The number of formulations containing concentrate camphor water is shown in parenthesis.

Table 2. Therapeutic and toxic doses of stomachic mixture components

composition	GI effect (dose/day)	amount of stomachic mixture required for GI effect	toxic dose in adult human	amount of stomachic mixture required for toxic effect
sodium bicarbonate	acid neutralization	45 ml as labeled	adverse cardiovascular effect (7.3 g/day equivalent to 2 g sodium (12))	183-405 ml*
rhubarb powder	laxative (1.5 g/day (18))	20 bottles*	no data	not estimable
peppermint oil	0.6-1.2 ml/day	300-1200 ml*	no data	no data
compound cardamom tincture	protective effect (0.64 g/day (58, 62))	not estimable	no data	not estimable
camphor	cooling sensation (5% w/w approximate to 50 mg/ml)	6-60 ml	convulsion (5-12 g)	2500-6000 ml*
compound tinospora tincture	bitter tonic (no data)	not estimable	ID ₅₀ = 1 g/kg	not estimable
ginger tincture	antiemesis (2 ml/day (93))	30-150 ml	mild GI side effects (5-8 ml/day (97))	75-600 ml*
compound gentian tincture	appetite stimulation (3 ml/day (124))	45-300 ml*	no data	no data
aromatic ammonia spirit	not known (no data)	not estimable	irritation dose (30 µg/ml)	not toxic
ipecacuanha tincture	induced emesis (15- 30 ml once)	60-120 ml*	fatal dose (100 ml (145))	5000 ml*

*Exceeding the recommended daily consumption amount of stomachic mixture (45 ml)

Rhubarb (Polygonaceae)

Rhubarb (Rhizoma Rhei, Chinese rhubarb, koton-nam-tao) is the root and rhizome of *Rheum officinale* Baill. or *R. palmatum* L. (14). While another species of *Rheum*, *R. rhabarbarum*, is used as food, Chinese rhubarb has been used primarily as herbal medicine for the treatment of the gastrointestinal (GI) tract (14) and kidney disorders (15). The major constituents of Chinese rhubarb are anthraquinone and its glycoside derivatives e. g. emodin, rhein, sennosides, and rheiniosides. Sennosides and rheiniosides are irritants, thus stimulating the motility of large intestinal (14, 16).

The laxative effects of rhubarb in GI tract are derived from the adrenaline antagonist activity, cholinergic neuron regulation, and aquaporin protein down-regulation (17). The laxative dose of rhubarb was reported as 0.5 g of powdered rhubarb for 3 times/day in critically ill patients (18) (Table 2).

Emodin and rhein help restore the balance of the intestinal flora, reduce injuries to the intestinal mucosa, and protect the liver from injuries during sepsis (19). In addition, *in vitro*, and *in vivo* studies have exhibited the benefits of rhubarb extract in oral cancer (20), hepatocellular carcinoma (21), pancreatitis (22,

23), anti-cariogenic bacteria (24) and anti-hepatitis-B viral infection (25). The potential side effects of Chinese rhubarb include GI discomfort, diarrhea (26), hepatotoxicity, and renal toxicity. A study in aged animals suggested that a high dose (40 g/kg/day) of ethanolic rhubarb extract has profound hepatic and renal toxicities (27, 28). Also, another animal experiment showed that rhubarb ethanolic extract caused liver fibrosis (15, 29). However, Chinese rhubarb demonstrates no serious adverse effects in human patients with chronic kidney disease (30). WHO recommends against the use of Chinese rhubarb in pregnancy and breastfeeding women according to insufficient safety data and possible adverse effects from its stimulant action (14). Furthermore, Chinese rhubarb can activate p-glycoprotein, thus causing a drug-herb interaction by reducing the GI absorption of phenytoin (31). In addition, anthranoids in rhubarb can diminish drug absorption by decreasing GI transit time (32).

Peppermint oil (Lamiaceae)

Peppermint oil is extracted from leaves of *Mentha piperita* L. It contains menthol as a major component and contains rosmarinic acid, terpenes, and flavonoids, primarily eriocitrin, luteolin, and hesperidin (33). The major constituents are menthol (30-55%) and menthone (14-32%). Other monoterpenes present are limonene (1-5%), cineole (3, 5-14%), menthofuran (1-9%), isomenthone (1.5-10%), menthyl acetate (2.8-10%), pulegone (up to 4%), carvone (up to 1%) with a ratio of cineole content to limonene content greater than 2 (34).

The use of peppermint oil for therapeutic purposes has been well established. Scientific evidence supports the use of peppermint oil in irritable bowel syndrome (35, 36), colonic spasm in patients undergoing barium enema, and non-ulcer dyspepsia (37). The antispasmodic effect might be the result of smooth muscle relaxation from the calcium channel

antagonist activity of the peppermint oil (38). Other uses of peppermint oil include the topical application for treating headache (37), pruritus, dermatitis (39), and promoting hair growth (40). In the stomachic mixture, peppermint oil is used as an antispasmodic and a flavoring agent. The therapeutic use of oral peppermint oil is 0.3 ml/day in children whose weight is lower than 45 kg and 0.6-1.2 ml/day in adults (35) which are equivalent to 300 ml - 1200 ml of the stomachic mixture (Table 2). It is therefore prudent to assume that peppermint oil from the stomachic mixture is unlikely to be toxic. However, the ingestion of high doses of peppermint oil is toxic to the liver and kidney and can also cause shock (41). Other common side effects include heartburn, perianal burning, blurred vision, nausea, and vomiting (37).

Allergy (42-46) or anaphylaxis (47, 48) caused by peppermint is not uncommon. Peppermint oil is safe for short-term use (4-7 days) as aromatherapy in pregnancy (49, 50). However, the safety data on oral use of peppermint oil in pregnant women are conflicting since one study showed that having two spoons of menthol leaves a day did not cause immediate danger in pregnant women (51), while another study showed that the oil can trigger menstruation (37). A study suggested that peppermint tea should be used cautiously in patients with GI reflux, hiatal hernia, or kidney stones (33). Peppermint oil has several potential interactions with drugs. It can inhibit glucose uptake in rats (52) and can also inhibit CYP450 1A2 (53) which leads to interaction with several medications such as cyclosporin (54). A case report demonstrated that peppermint oil increases the oral bioavailability of felodipine and simvastatin (55). *In vitro* study showed an anticholinesterase inhibitor activity of peppermint oil (56), thus it might interfere with cholinergic agonists or antagonists. In addition, the *in vivo* research found the competitive antagonism at calcium channels and increased the potentiality of calcium-channel blockers interaction (34).

Cardamom (Zingiberaceae)

Two cardamom species are available in Thailand. True cardamom (cardamom) is the fruits of *Elettaria cardamomum* L. Fruits of plants in genus *Amomum* (*Amomum krervanh* or Thai kravanh) are also called cardamom (57). The major chemical constituents in cardamom oil include monoterpene volatile oils (e.g. pinene, limonene, terpinyl acetate) and other minor components (e.g. hydrocarbons, carboxylic acids, aldehydes, and alcohols). Cardamom is used for culinary purposes while its volatile oils are mainly used as flavoring agents and perfume.

The use of cardamom for medicinal purposes is not well established. *In vitro* and *in vivo* studies showed antimicrobial (58), cytotoxic, anticarcinogenic properties (59, 60), and gastroprotective effect (61) of cardamom. In addition, a human study showed that cardamom at the dose of 3 g/day reduced fatty liver (62). Since crude cardamom (58) yields 8% cardamom oil, the therapeutic dose of cardamom oil can be speculated as 0.64 g per day (Table 2).

A study in mice found that the ethanol extract of *E. cardamomum* was safe at the dose of 30 μ g/g body weight and was toxic at the dose of 300 μ g/g (58). The toxicity includes weight loss and increasing creatine phosphokinase. This study also showed that the extract at the dose of 3 mg/g was lethal while another mice study showed that essential oils in cardamom at the dose of 0.75 mL/kg were not lethal (63). Allergic reaction to cardamom in humans has been reported (64) but rare (65). Haematuria from the ingestion of cardamom is also possible (64). Moreover, information on cardamom use in pregnancy and lactation is scarce. There is a study demonstrating the negative effects of cardamom on breastfed mice (66). Therefore, the use of cardamom in breastfeeding women should be discouraged. Also, there are studies that cardamom seeds oil can interfere with medications, such as liver inflammatory and gallstones drugs (67, 68).

Tinospora (Menispermaceae)

Tinospora is a genus of medicinal plants used widely in ethnomedicine. In Thailand, the major species used is *T. crispa* (L.) Hook. f. & Thomson (69). The stem of *Tinospora* contains alkaloids, the main component, and the others e.g. terpenoids, phenolics, steroids, aliphatic compounds, and polysaccharides (70). The alkaloids in *Tinospora* is a bitter tonic and can be used as a substitution for gentian in the stomachic mixture. *Tinospora* has been used in Ayurvedic and Chinese medicine as immunomodulatory (71, 72) and hypoglycemic medicine (73).

Other pharmacological effects of *Tinospora* include anticancer (74), analgesics, anti-inflammatory, antipyretics (75), and positive bone effects (76). Although the information on the GI pharmacology of *Tinospora* is insufficient, studies demonstrate that *Tinospora* is safe. The LD₅₀ of *Tinospora* in human extrapolated from animals is higher than 1 g/kg orally (77). A human study indicated that an aqueous extract of *Tinospora* at a dose of 500 mg was safe in humans (78). It is safe to assume that the usual dose of the stomachic mixture contains a nontoxic amount of *Tinospora* (Table 2). However, *Tinospora* contains furanoditerpenoids (79) and is hepatotoxic in humans (80, 81). Drug interactions with *Tinospora* via pharmacokinetic or pharmacodynamic mechanisms are possible. *Tinospora* should be used with caution in diabetes patients since it has hypoglycemic effects and can interact with glibenclamide *in vivo* (82). An *in vitro* experiment showed that *Tinospora* methanolic extract (0.5mg/ml) inhibited CYP3A4 (83). *Tinospora* might have pharmacodynamic interactions with diuretics (84), cholinergic (85), and dopaminergic (86) drugs. *Tinospora* shows a positive effect on lactation in a study in cows (87) and does not show teratogenicity in a mice study (88). However, the information on the use of *Tinospora* in lactating and pregnant women is unavailable.

Ginger (Zingiberaceae)

Ginger is the rhizome of *Zingiber officinale* Roscoe which has been used as spices and herbs in Asia. It has various medicinal uses including anti-inflammatory (89), antimigraine, antidiabetes (90), and anticancer (91). The most studied property of ginger is its antinausea and vomiting properties, especially during pregnancy (92) and chemotherapy (93, 94). The pharmacological properties of ginger derive from its muscarinic agonist and serotonergic agonist activity (95) which leads to the relaxation of the lower esophageal sphincter and the decrease of esophageal contraction velocity (93). Ginger can be consumed at the amount as high as 4 g of ginger rhizome per day (93). However, a recommended safe effective daily dose of ginger in human studies is 1,000 mg of ginger rhizome which is equivalent to 2 ml of the liquid ginger extract (93) or 30-150 ml of the stomachic mixture (Table 2). Side effects of ginger include a mild headache, fever, sweating, thirst, belching, diarrhea, and somnolence (96). Mild GI side effects e.g. belching, bad taste in the mouth, stomach upset, and heartburn were reported in patients using 2,500–4,000 mg of dried ginger rhizomes (97). A case report showed that chronic use of ginger caused dysuria (98) and subacute thyroiditis (99). Allergy to ginger has been reported in several case reports (100-102). In addition, ginger can be used safely as an antiemetic in pregnant women (103) and a galactagogue in breastfeeding mothers without side effects (104). Ginger might potentiate anticoagulant and antiarrhythmic effects of the medicine. Therefore, it should be used with caution in patients treated with anticoagulants and antiarrhythmics (105).

Camphor (Lauraceae)

Camphor (1,7,7- Trimethylbicyclo[2.2.1]-2-heptanone) is a ubiquitous chemical found in herbs e.g. basil, coriander, and sage; food and beverages; over the counter topical medications e.g. topical analgesic balm, topical nasal decongestant balm, and household

products e.g. moth repellent (106, 107). Camphor can be extracted from the old stem and root of *Cinnamomum camphora* (L.) J. Presl or synthesized from α -pinene. Traditional medicine uses camphor as the central nervous system, heart, and sex- drive stimulants (108). Camphor was also used as a contraceptive, abortive agent, and lactation suppressant (108-110). These indications of camphor are usually abused and lead to camphor poisoning (111). Camphor is also used in cold remedies and liniments for musculoskeletal pain (108). The reason for the use of camphor in the stomachic mixture is not known but its cooling sensation stimulating effect via transient receptor potential melastatin 8 (112) and transient receptor potential vanilloid subtype 1 channel (113) may be the reason. The cooling effect occurs at a dose of 5% w/w (114). The approximate amount of camphor in the stomachic mixture is 2 mg/ml which is lower than reported fatal doses which in infants is approximately 6 g; in unborn infants is approximately 10 g (115) and in adults is 50-100 mg/kg (Table 2) (109). At the dose of 100 mg, camphor can lead to hospitalization from nausea, vomiting, and altered mental status (116). Other side-effects of camphor include delusion (117), seizure (118-121), and myocarditis (122). A case report showed that seizure occurred at a dose of 68 mg/kg (123). Therefore, the camphor-containing stomachic mixture should be avoided in patients with a history of seizure or status epilepticus. It should be also avoided in pregnant women because camphor has an abortive effect and fetal deaths were reported in pregnant mothers who ingested 30 grams of camphor (108). Camphor can suppress milk production; therefore, the use of breastfeeding women should be discouraged.

Gentian (Gentianaceae)

Gentian tincture is an alcoholic extract of the root of *Gentiana lutea* L., yellow gentian (124). It should not be confused with gentian violet which is a triphenylmethane dye with antiseptic properties (125).

The major constituents of gentian root include secoiridoid glycosides (bitter substances), xanthones, carbohydrates, volatile oils, phytosterols, and triterpenes. The proposed mechanism of digestion stimulating effect of these substances in gentian was via the cephalic-response pathway, i.e. by acting in the cerebral cortex, and local-response pathway, i.e. by binding to bitter receptors in the upper GI tract (126). Because of the digestion stimulating activities, the medicinal use of gentian tincture is to stimulate appetites and relieve flatulence. Because the daily dose of gentian is one ml of tincture every eight hours (127), the approximate amount of gentian tincture in the stomachic mixture should not have therapeutic or side-effects (Table 2). Side-effects of gentian are uncommon and include flatulence, nausea, stomach cramps or spasms, soft feces, and headache (127). Most of the case reports of the toxicity of gentian occur with the adulteration of gentian with *Veratrum album* (128, 129). *Gentiana* should not be used in pregnant women since it can cause spontaneous abortion (126).

Ipecacuanha (Rubiaceae)

Roots of *Cephaelis ipecacuanha* (Brot.) A. Rich. (ipecacuanha) have two major alkaloids, emetine, and cephaeline, which cause vomiting and diarrhea (130). Emetine and cephaeline bind to several receptors including 5-HT1A, 5-HT3, 5-HT4, dopamine, nicotinic, muscarinic- 3, and β_1 -adrenergic receptors (131); therefore, ipecac has potentials for drug interactions. Ipecacuanha has been formulated as ipecac syrup which was mainly used for GI decontamination after the ingestion of toxic substances (132, 133). The use of ipecac syrup to induce emesis in patients with drug overdose or toxin exposure has been drastically reduced since the American Academy of Clinical Toxicology and the European Association of Poison Centres and Clinical Toxicologists have released their guidelines in 2004. The dose of ipecac syrup for emesis induction is 15-30 ml once (134). The amount of total

alkaloids in the tincture of ipecac and ipecac syrup is 2 mg/ ml (135) and 1.57 mg/ ml (4), respectively. Therefore, 12-24 ml of ipecac tincture or 60-120 ml of the ipecac-containing stomachic mixture are adequate to induce emesis (Table 2). Poisoning of ipecac, accidentally or intentionally in bulimia patients, is frequently reported (136, 137) and results in death (138, 139). Ipecac related mortality results from cardiomyopathy including arrhythmias and myositis (140). Cephaeline and emetine can also cause gastroesophageal tears, diarrhea, alkalosis, hypokalemia, and dehydration (139). As a result, warning on the label of the stomachic mixture states that it should be avoided in patients with cardiac conditions (2).

Aromatic ammonia spirit

Aromatic ammonia spirit is a hydroalcoholic solution containing, per 100 ml, 1.7-2.1 g of NH_3 and 3.5-4.5 g of $(\text{NH}_4)_2\text{CO}_3$ (4). The amount of aromatic ammonia spirit in the stomachic mixture is 8 $\mu\text{l}/\text{ml}$. Therefore, the stomachic mixture contains 1.36-1.68 μg of NH_3 and 2.8-3.6 μg of $(\text{NH}_4)_2\text{CO}_3$ per ml. Inhalation of ammonia from stomachic mixture does not cause health concerns because the amount is lower than the lowest amount of ammonia that can be detected by the human (5 ppm or 5 $\mu\text{l}/\text{ml}$; 1 ppm equals 1 $\mu\text{g}/\text{ml}$) and the lowest irritation dose (30 ppm for 10 minutes) (Table 2) (141). Ingestion of ammonia causes GI irritation (142) but rarely causes systemic side effects (143). Consumption of a high amount of ammonia that increases the serum concentration of ammonia can be toxic to the brain (144). However, with an insignificant amount of ammonia in the stomachic mixture, it is less likely to cause any side effects from the ingestion.

Conclusions

The stomachic mixture, an antacid, contains sodium bicarbonate as an active ingredient. Sodium content in stomachic mixture is high and should be

monitored in patients requiring sodium restriction. Other components in stomachic mixture are usually at the concentration lower than effective doses. However, some of them demonstrate similar toxicity profiles. For example, rhubarb and peppermint oil are renal and hepatotoxic. Rhubarb, ginger, gentian, and ipecac can cause diarrhea. Cardiotoxicity can occur from using gentian, ipecac, and camphor. Camphor and ammonia spirit can cause CNS side effects. The hypoglycemic effect is caused by peppermint oil and *Tinospora*. Since the safety data on the combined use of these components or on the use of stomachic mixture is not available, it is prudent to avoid the use in patients with the aforementioned conditions. In addition, there is no safety data regarding the use of stomachic mixture in pregnant and breastfeeding women. The use of stomachic mixture in pregnant women should be avoided since rhubarb, peppermint oil, camphor, gentian, and ipecac have negative effects on pregnancy. Stomachic mixture should not be used in patients who are allergic to its components since several components e.g. peppermint oil can cause severe allergic reactions.

References

- Batchelor HK, Marriott JF. Paediatric pharmacokinetics: key considerations. *Br J Clin Pharmacol*. 2015; 79: 395-404.
- Public Health Ministerial Declaration on Modern household drugs. Royal Gazette No. 116, Part 38D (May 12, 1999).
- Midlöv P, Martin A, Ostgren CJ, Mölstad S. Depression and use of antidepressants in Swedish nursing homes: a 12-month follow-up study. *Int Psychoger* 2014; 26: 669-75.
- The United States Pharmacopeia 35. National formulary 30. Rockville (MD): United States Pharmacopeial Convention; 2011.
- Daodee S, Wangboonsakul J, Jurakamjorn K. Quantitative and qualitative determination of alcohols in stomachica and carminative mixture by gas chromatographic method with mass spectrometry. *KKU Research Journal* 1999; 4: 8.
- Lin MS, Sun P, Yu HY. Evaluation of buffering capacity and acid neutralizing- pH time profile of antacids. *J Formos Med Assoc* 1998; 97: 704-10.
- Smith ME, Morton DG. 4. The stomach: control. In: Smith ME, Morton DG, editors. *The digestive system* 2nd ed. Churchill: Livingstone; 2010. p. 51-69.
- Fordtran JS, Morawski SG, Santa Ana CA, Rector FC, Jr. Gas production after reaction of sodium bicarbonate and hydrochloric acid. *Gastroenterology*. 1984; 87: 1014-21.
- Thomas SH, Stone CK. Acute toxicity from baking soda ingestion. *Am J Emerg Med* 1994; 12: 57-9.
- Durkalec-Michalski K, Zawieja EE, Podgórski T, Łoniewski I, Zawieja BE, Warzybok M, et al. The effect of chronic progressive- dose sodium bicarbonate ingestion on CrossFit-like performance: A double- blind, randomized cross- over trial. *PLoS one*. 2018; 13: e0197480.
- Appel LJ, Frohlich ED, Hall JE, Pearson TA, Sacco RL, Seals DR, et al. The importance of population-wide sodium reduction as a means to prevent cardiovascular disease and stroke: a call to action from the American Heart Association. *Circulation*. 2011; 123: 1138-43.
- World Health Organization. Guideline: Sodium intake for adults and children [online]. 2012 [cited Mar 14, 2020]. Available from: www.who.int/iris/handle/10665/77985.
- Craighead A. A descriptive survey of advanced practice registered nurses' preparedness for treating geriatric depression [online]. 2017 [cited Mar 14, 2020]. Available from: www.who.int/iris/handle/10665/77985.
- World Health Organization. Rhubarb. [online]. 1999 [cited Mar 14, 2020]. Available from: apps.who.int/medicinedocs/en/d/Js2200e/.

15. Zhang ZH, Vaziri ND, Wei F, Cheng XL, Bai X, Zhao YY. An integrated lipidomics and metabolomics reveal nephroprotective effect and biochemical mechanism of *Rheum officinale* in chronic renal failure. *Sci Rep* 2016; 6: 22151.
16. Kon R, Ikarashi N, Nagoya C, Takayama T, Kusunoki Y, Ishii M, et al. Rheinanthrone, a metabolite of sennoside A, triggers macrophage activation to decrease aquaporin-3 expression in the colon, causing the laxative effect of rhubarb extract. *J Ethnopharmacol*. 2014; 152: 190-200.
17. Cao Y-J, Pu Z-J, Tang Y-P, Shen J, Chen Y-Y, Kang A, et al. Advances in bio-active constituents, pharmacology and clinical applications of rhubarb. *Chin Med*. 2017; 12: 36.
18. Shimizu K, Kageyama M, Ogura H, Yamada T, Shimazu T. Effects of rhubarb on intestinal dysmotility in critically ill patients. *Intern Med*. 2018; 57: 507-10.
19. Lai F, Zhang Y, Xie D-p, Mai S-t, Weng Y-n, Du J-d, et al. A systematic review of rhubarb (a traditional Chinese medicine) used for the treatment of experimental sepsis. *Evid Based Complement Alternat Med* 2015; 2015: 131283.
20. Chen YY, Hsieh MJ, Hsieh YS, Chang YC, Chen PN, Yang SF, et al. Antimetastatic effects of *Rheum palmatum* L. extract on oral cancer cells. *Environ Toxicol*. 2017; 32: 2287-94.
21. El-Saied MA, Sobeh M, Abdo W, Badr OM, Youssif LT, Elsayed IH, et al. *Rheum palmatum* root extract inhibits hepatocellular carcinoma in rats treated with diethylnitrosamine. *J Pharm Pharmacol*. 2018; 70: 821-9.
22. Zhang WF, Li ZT, Fang JJ, Wang GB, Yu Y, Liu ZQ, et al. Expression and clinical significance of rhubarb on serum amylase and TNF-alpha of rat model of acute pancreatitis. *J Biol Regul Homeost Agents*. 2017; 31: 753-60.
23. Xiong Y, Chen L, Fan L, Wang L, Zhou Y, Qin D, et al. Free total rhubarb anthraquinones protect intestinal injury via regulation of the intestinal immune response in a rat model of severe acute pancreatitis. *Front Pharmacol*. 2018; 9 :75.
24. Wang S, Fan M, Bian Z. Experimental study of bacteriostatic activity of Chinese herbal medicines on primary cariogenic bacteria in vitro. *Zhonghua Kou Qiang Yi Xue Za Zhi*. 2001; 36: 385-7.
25. Sun Y, Li L-j, Li J, Li Z. Inhibition of hepatitis B virus replication by *Rheum palmatum* L. ethanol extract in a stable HBV-producing cell line. *Virologica Sinica*. 2007; 22: 14-20.
26. Wang JK, Li A, Wang H, Xu XY. Comparative studies on purgative potency among three species of certified rhubarb. *Zhongguo Zhong Yao Za Zhi*. 2006; 31: 1987-91.
27. Wang JB, Kong WJ, Wang HJ, Zhao HP, Xiao HY, Dai CM, et al. Toxic effects caused by rhubarb (*Rheum palmatum* L.) are reversed on immature and aged rats. *J Ethnopharmacol*. 2011; 134: 216-20.
28. Zhang Z-H, Vaziri ND, Wei F, Cheng X-L, Bai X, Zhao YY. An integrated lipidomics and metabolomics reveal nephroprotective effect and biochemical mechanism of *Rheum officinale* in chronic renal failure. *Sci Rep*. 2016; 6: 22151.
29. Wang JB, Zhao HP, Zhao YL, Jin C, Liu DJ, Kong WJ, et al. Hepatotoxicity or hepatoprotection? Pattern recognition for the paradoxical effect of the Chinese herb *Rheum palmatum* L. in treating rat liver injury. *PLoS one*. 2011; 6: e24498.
30. Wang H, Song H, Yue J, Li J, Hou YB, Deng JL. *Rheum officinale* (a traditional Chinese medicine) for chronic kidney disease. *Cochrane Database Syst Rev*. 2012; 7: Cd008000.
31. Chi Y-C, Juang S-H, Chui WK, Hou Y-C, Chao P-DL. Acute and chronic administrations of *rheum palmatum* reduced the bioavailability of phenytoin in rats: a new herb-drug interaction. *Evid Based Complement Alternat Med* 2012; 2012: 9.

32. Vahabi S, Eatemadi A. Phyto-anesthetics: A mini-review on herb- anaesthesia drug interactions. *Biomed Pharmacother* 2016; 84: 1885-90.

33. McKay DL, Blumberg JB. A review of the bioactivity and potential health benefits of peppermint tea (*Mentha piperita* L.). *Phytother Res*. 2006; 20: 619-33.

34. European Medical Agency. Assessment report on *Mentha X piperita* L., Aetheroleum [online]. 2008 [cited Mar 14, 2020]. Available from: www.ema.europa.eu/en/documents/herbal-report/assessment-report-mentha-x-piperita-l-aetheroleum_en.pdf.

35. Khanna R, MacDonald JK, Levesque BG. Peppermint oil for the treatment of irritable bowel syndrome: a systematic review and meta-analysis. *J Clinical Gastroenterol* 2014; 48: 505-12.

36. Cappello G, Spezzaferro M, Grossi L, Manzoli L, Marzio L. Peppermint oil (Mintoil) in the treatment of irritable bowel syndrome: a prospective double blind placebo-controlled randomized trial. *Dig Liver Dis* 2007; 39: 530-6.

37. Kligler B, Chaudhary S. Peppermint oil. *American family physician*. 2007; 75: 1027-30.

38. Chumpitazi BP, Kearns GL, Shulman RJ. Review article: the physiological effects and safety of peppermint oil and its efficacy in irritable bowel syndrome and other functional disorders. *Aliment Pharmacol Ther*. 2018; 47: 738-52.

39. Herro E, Jacob SE. *Mentha piperita* (peppermint). *Dermatitis*. 2010; 21: 327-9.

40. Oh JY, Park MA, Kim YC. Peppermint oil promotes hair growth without toxic signs. *Toxicol Res* 2014; 30: 297-304.

41. Nath SS, Pandey C, Roy D. A near fatal case of high dose peppermint oil ingestion- Lessons learnt. *Indian J Anaesth* 2012; 56: 582-4.

42. Tran A, Pratt M, DeKoven J. Acute allergic contact dermatitis of the lips from peppermint oil in a lip balm. *Dermatitis* 2010; 21: 111-5.

43. Bourgeois P, Goossens A. Allergic contact cheilitis caused by menthol in toothpaste and throat medication: a case report. *Contact Derm* 2016; 75: 113-5.

44. Vermaat H, van Meurs T, Rustemeyer T, Bruynzeel DP, Kirtschig G. Vulval allergic contact dermatitis due to peppermint oil in herbal tea. *Contact Derm* 2008; 58: 364-5.

45. Kalavala M, Hughes TM, Goodwin RG, Anstey AV, Stone NM. Allergic contact dermatitis to peppermint foot spray. *Contact Derm* 2007; 57: 57-8.

46. Tamir S, Davidovich Z, Attal P, Eliashar R. Peppermint oil chemical burn. *Otolaryngol Head Neck Surg*. 2005; 133: 801-2.

47. Bayat R, Borici-Mazi R. A case of anaphylaxis to peppermint. *Allergy Asthma Clin Immunol*. 2014; 10: 6.

48. Szema AM, Barnett T. Allergic reaction to mint leads to asthma. *Allergy Rhino (Providence)* 2011; 2: 43-5.

49. Pasha H, Behmanesh F, Mohsenzadeh F, Hajahmadi M, Moghadamnia AA. Study of the effect of mint oil on nausea and vomiting during pregnancy. *Iran Red Crescent Med J* 2012; 14: 727-30.

50. Joulaeerd N, Ozgoli G, Hajimehdipoor H, Ghasemi E, Salehimoghaddam F. Effect of aromatherapy with peppermint oil on the severity of nausea and vomiting in pregnancy: a single-blind, randomized, placebo-controlled trial. *J Reprod Infertil*. 2018; 19: 32-8.

51. Ahmed EMS, Soliman S, Mahmoud HM. Effect of peppermint as one of carminatives on relieving gastroesophageal reflux disease (GERD) during pregnancy [online]. 2012 [cited Mar 14, 2020]. Available from: [www.semanticscholar.org/paper/Effect-of-Peppermint-as-One-of-Carminatives-on-\(-\)-Ahmed-Soliman/b3c40fb530b8cdcdf1afb952256c365ec0287dc3](http://www.semanticscholar.org/paper/Effect-of-Peppermint-as-One-of-Carminatives-on-(-)-Ahmed-Soliman/b3c40fb530b8cdcdf1afb952256c365ec0287dc3).

52. Beesley A, Hardcastle J, Hardcastle PT, Taylor CJ. Influence of peppermint oil on absorptive and

secretory processes in rat small intestine. *Gut*. 1996; 39: 214-9.

53. Dresser GK, Wacher V, Wong S, Wong HT, Bailey DG. Evaluation of peppermint oil and ascorbyl palmitate as inhibitors of cytochrome P4503A4 activity in vitro and in vivo. *Clin Pharmacol Ther*. 2002; 72: 247-55.

54. Wacher VJ, Wong S, Wong HT. Peppermint oil enhances cyclosporine oral bioavailability in rats: comparison with D-alpha-tocopheryl poly(ethylene glycol 1000) succinate (TPGS) and ketoconazole. *J Pharm Sci*. 2002; 91: 77-90.

55. Dresser GK, Wacher V, Ramtoola Z, Cumming K, Bailey D. Peppermint oil increases the oral bioavailability of felodipine and simvastatin. *Clin Pharmacol Ther* 2002; 71: 67.

56. Miyazawa M, Watanabe H, Umemoto K, Kameoka H. Inhibition of acetylcholinesterase activity by essential oils of *mentha* species. *J Agric Food Chem* 1998; 46: 3431-4.

57. Madhusoodanan KJ, Rao YS. 10 Cardamom (large). In: Peter KV, editor. *Handbook of herbs and spices*. Cambridge: Woodhead Publishing; 2001. p. 134-42.

58. El Malti J, Mountassif D, Amarouch H. Antimicrobial activity of *Elettaria cardamomum*: Toxicity, biochemical and histological studies. *Food Chem* 2007; 104: 1560-8.

59. Das I, Acharya A, Berry DL, Sen S, Williams E, Permaul E, et al. Antioxidative effects of the spice cardamom against non-melanoma skin cancer by modulating nuclear factor erythroid-2-related factor 2 and NF- κ B signalling pathways. *Br J Nutr*. 2012; 108: 984-97.

60. Sengupta A, Ghosh S, Bhattacharjee S. Dietary cardamom inhibits the formation of azoxymethane-induced aberrant crypt foci in mice and reduces COX-2 and iNOS expression in the colon. *Asian Pac J Cancer Prev*. 2005; 6: 118-22.

61. Jamal A, Javed K, Aslam M, Jafri MA. Gastroprotective effect of cardamom, *Elettaria cardamomum* Maton. fruits in rats. *J Ethnopharmacol*. 2006; 103: 149-53.

62. Daneshi-Maskooni M, Keshavarz SA, Qorbani M, Mansouri S, Alavian SM, Badri-Fariman M, et al. Green cardamom increases Sirtuin-1 and reduces inflammation in overweight or obese patients with non-alcoholic fatty liver disease: a double-blind randomized placebo-controlled clinical trial. *Nutr Metab (Lond)*. 2018; 15: 63.

63. Masoumi-Ardakani Y, Mandegary A, Esmaeilpour K, Najafipour H, Sharififar F, Pakravan M, et al. Chemical composition, anticonvulsant activity, and toxicity of essential oil and methanolic extract of *Elettaria cardamomum*. *Planta medica*. 2016; 82: 1482-6.

64. Mobacken H, Fregert S. Allergic contact dermatitis from cardamom. *Contact Derm* 1975; 1: 175-6.

65. Dooms-Goossens A, Dubelloy R, Degreef H. Contact and systemic contact-type dermatitis to spices. *Dermatol Clin*. 1990; 8: 89-93.

66. Abu-Taweel GM. Cardamom (*Elettaria cardamomum*) perinatal exposure effects on the development, behavior and biochemical parameters in mice offspring. *Saudi J Biol Sci*. 2018; 25: 186-93.

67. Sengottuvelu S. Chapter 34 - Cardamom (*Elettaria cardamomum* Linn. Maton) Seeds in Health. In: Preedy VR, Watson RR, Patel VB, editors. *Nuts and Seeds in health and disease prevention*. San Diego: Academic Press; 2011. p. 285-91.

68. Aboelnaga SMH. Effect of some levels of cardamom, clove and anise on hepatotoxicity in rats caused by CCL4. *World Appl Sci J* 2015; 33:11.

69. Ahmad W, Jantan I, Bukhari SN. *Tinospora crispa* (L.) Hook. f. & Thomson: A review of its ethnobotanical, phytochemical, and pharmacological aspects. *Front Pharmacol*. 2016; 7: 59.

70. Singh D, Chaudhuri PK. Chemistry and pharmacology of *Tinospora cordifolia*. *Nat Prod Commun*. 2017; 12: 299-308.

71. Haque MA, Jantan I, Abbas Bukhari SN. *Tinospora* species: An overview of their modulating effects on the immune system. *J Ethnopharmacol*. 2017; 207: 67-85.

72. Dhama K, Sachan S, Khandia R, Munjal A, Iqbal HMN, Latheef SK, et al. Medicinal and beneficial health applications of *Tinospora cordifolia* (Gudu chi) : A miraculous herb countering various diseases/ disorders and its immunomodulatory effects. *Recent Pat Endocr Metab Immune Drug Discov*. 2017; 10: 96-111.

73. Thomas A, Rajesh EK, Kumar DS. The significance of *Tinospora crispa* in treatment of diabetes mellitus. *Phytother Res*. 2016; 30: 357-66.

74. Bansal P, Malik MA, Das SN, Kaur J. *Tinospora cordifolia* induces cell cycle arrest in human oral squamous cell carcinoma cells. *Gulf J Oncolog*. 2017; 1: 10-4.

75. Hussain L, Akash MS, Ain NU, Rehman K, Ibrahim M. The analgesic, anti-inflammatory and anti-pyretic activities of *Tinospora cordifolia*. *Adv Clin Exp Med*. 2015; 24: 957-64.

76. Chi S, She G, Han D, Wang W, Liu Z, Liu B. Genus *Tinospora*: Ethnopharmacology, phytochemistry, and pharmacology. *Evid Based Complement Alternat Med* 2016; 2016: 32.

77. Rege NN, Thatte UM, Dahanukar SA. Adaptogenic properties of six rasayana herbs used in Ayurvedic medicine. *Phytother Res* 1999; 13: 275-91.

78. Singh RK. *Tinospora cordifolia* as an adjuvant drug in the treatment of hyper-reactive malarious splenomegaly--case reports. *J Vector Borne Dis*. 2005; 42: 36-8.

79. Cachet X, Langrand J, Riffault-Valois L, Bouzidi C, Colas C, Dugay A, et al. Clerodane furanoditerpenoids as the probable cause of toxic hepatitis induced by *Tinospora crispa*. *Sci Rep*. 2018; 8: 13520.

80. Langrand J, Regnault H, Cachet X, Bouzidi C, Villa AF, Serfaty L, et al. Toxic hepatitis induced by a herbal medicine: *Tinospora crispa*. *Phytomedicine*. 2014; 21: 1120-3.

81. Denis G, Gerard Y, Sahpaz S, Laporte R, Viget N, Ajana F, et al. Malarial prophylaxis with medicinal plants: toxic hepatitis due to *Tinospora crispa*. *Therapie* 2007; 62: 271-2.

82. Sahu R, Ahmed T, Sangana R, Punde R, Subudhi BB. Effect of *Tinospora cordifolia* aqua-alcoholic extract on pharmacokinetic of Glibenclamide in rat: An herb-drug interaction study. *J Pharm Biomed Anal*. 2018; 151: 310-6.

83. Subehan, Usia T, Iwata H, Kadota S, Tezuka Y. Mechanism- based inhibition of CYP3A4 and CYP2D6 by Indonesian medicinal plants. *J Ethno pharmacol*. 2006; 105: 449-55.

84. Nayampalli SS, Ainapure SS, Samant BD, Kudtarkar RG, Desai NK, Gupta KC. A comparative study of diuretic effects of *Tinospora cordifolia* and hydrochlorothiazide in rats and a preliminary phase I study in human volunteers. *J Postgrad Med*. 1988; 34: 233-6.

85. Yusoff M, Hamid H, Houghton P. Anticholinesterase inhibitory activity of quaternary alkaloids from *Tinospora crispa*. *Molecules*. 2014; 19: 1201-11.

86. Kosaraju J, Chinni S, Roy PD, Kannan E, Antony AS, Kumar MN. Neuroprotective effect of *Tinospora cordifolia* ethanol extract on 6-hydroxy dopamine induced Parkinsonism. *Indian J Pharmacol*. 2014; 46: 176-80.

87. Mallick S, Prakash BS. Influence of feeding *Tinospora cordifolia* peripartum on lactation parameters in crossbred cows. *J Anim Physiol Anim Nutr (Berl)*. 2012; 96: 1112-20.

88. Shivananjappa MM, Muralidhara. Abrogation of maternal and fetal oxidative stress in the streptozotocin- induced diabetic rat by dietary

supplements of *Tinospora cordifolia*. *Nutrition* 2012; 28: 581-7.

89. van Breemen RB, Tao Y, Li W. Cyclooxygenase-2 inhibitors in ginger (*Zingiber officinale*). *Fitoterapia*. 2011; 82: 38-43.

90. Ryan JL, Morrow GR. *Ginger*. *Oncol Nurse Ed* 2010; 24: 46-9.

91. Prasad S, Tyagi AK. *Ginger and its constituents: Role in prevention and treatment of gastrointestinal cancer*. *Gastroenterol Res Pract* 2015; 2015: 11.

92. Viljoen E, Visser J, Koen N, Musekiwa A. A systematic review and meta-analysis of the effect and safety of ginger in the treatment of pregnancy-associated nausea and vomiting. *Nutr J*. 2014; 13: 20.

93. Lete I, Allué J. The effectiveness of ginger in the prevention of nausea and vomiting during pregnancy and chemotherapy. *Integr Med Insights*. 2016; 11: 11-7.

94. Marx WM, Teleni L, McCarthy AL, Vitetta L, McKavanagh D, Thomson D, et al. *Ginger (*Zingiber officinale*) and chemotherapy-induced nausea and vomiting: a systematic literature review*. *Nutr Rev* 2013; 71: 245-54.

95. Ghayur MN, Khan AH, Gilani AH. *Ginger facilitates cholinergic activity possibly due to blockade of muscarinic autoreceptors in rat stomach fundus*. *Pak J Pharm Sci* 2007; 20: 231-5.

96. Shawahna R, Taha A. Which potential harms and benefits of using ginger in the management of nausea and vomiting of pregnancy should be addressed? a consensual study among pregnant women and gynecologists. *BMC Complement Altern Med*. 2017; 17: 204.

97. Altman RD, Marcussen KC. Effects of a ginger extract on knee pain in patients with osteoarthritis. *Arthritis Rheum* 2001; 44: 2531-8.

98. Akbarzadeh E, Heydari M, Atarzadeh F, Jaladat AM. Chronic dysuria following ginger (*Zingiber officinale*) use: A case report [online]. 2018 [cited Mar 14, 2020]. Available from: www.gmj.ir/index.php/gmj/article/view/1086/html.

99. Sanavi S, Afshar R. Subacute thyroiditis following ginger (*Zingiber officinale*) consumption. *Int J Ayurveda Res*. 2010; 1: 47-8.

100. Gehlhaar P, Gonzalez- de- Olano D, Madrigal-Burgaleta R, Bartolome B, Pastor-Vargas C. Allergy to ginger with cysteine proteinase GP- I as the relevant allergen. *Ann Allergy Asthma Immunol*. 2018; 121: 624-5.

101. Schmidt J, Dahl S, Sherson DL. Allergic rhinoconjunctivitis caused by occupational exposure to ginger. *Ugeskr Laeger*. 2015; 177: V12140723.

102. Sundquist B, Celestin J. P290 A spicey diagnosis: ginger hypersensitivity in an adolescent male. *Ann Allergy Asthma Immunol* 2016; 117: S108.

103. Borrelli F, Capasso R, Aviello G, Pittler MH, Izzo AA. Effectiveness and safety of ginger in the treatment of pregnancy- induced nausea and vomiting. *Obstet Gynecol* 2005; 105: 849-56.

104. Paritakul P, Ruangrongmorakot K, Laosooksathit W, Suksamarnwong M, Puapornpong P. The effect of ginger on breast milk volume in the early postpartum period: A randomized, double- blind controlled trial. *Breastfeed Med*. 2016; 11: 361-5.

105. White B. *Ginger: an overview*. *Am Fam Physician*. 2007; 75: 1689-91.

106. Peters AL, Dekker E, Michels WM. [Camphor poisoning following ingestion of mothballs 'for headache']. *Ned Tijdschr Geneeskd*. 2011; 155: A3676.

107. Moss MJ, Maskell KF, Hieger MA, Wills BK, Cumpston KL. An algorithm for identifying mothball composition *Clin Toxicol (Phila)*. 2017; 55: 919-21.

108. Manoguerra AS, Erdman AR, Wax PM, Nelson LS, Caravati EM, Cobaugh DJ, et al. Camphor poisoning: an evidence-based practice guideline for out-of-hospital management. *Clin Toxicol (Phila)*. 2006; 44: 357-70.

109. Rabl W, Katzgraber F, Steinlechner M. Camphor ingestion for abortion (case report). *Forensic Sci Int*. 1997; 89: 137-40.

110. Shahabi S, Jorsaraei SG, Akbar Moghadamnia A, Barghi E, Zabihi E, Golsorkhtabar Amiri M, et al. The effect of camphor on sex hormones levels in rats. *Cell J*. 2014; 16: 231-4.

111. Köppel C, Tenczer J, Schirop T, Ibe K. Camphor poisoning. *Arch Toxicol* 1982; 51: 101-6.

112. Selescu T, Ciobanu AC, Dobre C, Reid G, Babes A. Camphor activates and sensitizes transient receptor potential melastatin 8 (TRPM8) to cooling and icilin. *Chem Senses*. 2013; 38: 563-75.

113. Xu H, Blair NT, Clapham DE. Camphor activates and strongly desensitizes the transient receptor potential vanilloid subtype 1 channel in a vanilloid-independent mechanism. *J Neurosci* 2005; 25: 8924-37.

114. Kotaka T, Kimura S, Kashiwayanagi M, Iwamoto J. Camphor induces cold and warm sensations with increases in skin and muscle blood flow in human. *Bio Pharm Bul* 2014; 37: 1913-8.

115. Miller D. The toxicity of camphor (camphorated oil). *J Am Med Assoc* 1914; 63: 579.

116. Ragucci KR, Trangmar PR, Bigby JG, Detar TD. Camphor ingestion in a 10-year-old male. *South Med J*. 2007; 100: 204-7.

117. Lim GC, Chen YF, Liu L, Huang SC, Lin KK, Hsiao CH. Camphor-related self-inflicted keratoconjunctivitis complicating delusions of parasitosis. *Cornea*. 2006; 25: 1254-6.

118. Mathen PG, Sreekrishnan TP, Kumar KPG, Mohan N. Camphor poisoning: A rare cause of acute symptomatic seizures in children. *J Emerg Trauma Shock* 2018; 11: 228-9.

119. Guibert J, Flamant C, Hallalel F, Douummar D, Frata A, Renolleau S. Anti-flatulence treatment and status epilepticus: a case of camphor intoxication. *Emerg Med J*. 2007; 24: 859-60.

120. Khine H, Weiss D, Graber N, Hoffman RS, Esteban -Cruciani N, Avner JR. A cluster of children with seizures caused by camphor poisoning. *Pediatrics*. 2009; 123: 1269-72.

121. Michiels EA, Mazor SS. Toddler with seizures due to ingesting camphor at an Indian celebration. *Pediatr Emerg Care*. 2010; 26: 574-5.

122. Bhaya M, Beniwal R. Camphor induced myocarditis: a case report. *Cardiovasc Toxicol*. 2007; 7: 212-4.

123. Lahoud CA, March JA, Proctor DD. Campho-Phenique ingestion: an intentional overdose. *South Med J*. 1997; 90: 647-8.

124. Knöss W. Assessment report on *Gentiana lutea* L., Radix [online]. 2018 [cited Mar 14, 2020]. Available from: www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-gentiana-lutea-l-radix-revision-1_en.pdf.

125. Maley AM, Arbiser JL. Gentian violet: a 19th century drug re-emerges in the 21st century. *Exp Dermatol* 2013; 22: 775-80.

126. Mirzaee F, Hosseini A, Jouybari HB, Davoodi A, Azadbakht M. Medicinal, biological and phytochemical properties of *Gentiana* species. *J Tradit Complement Med* 2017; 7: 400-8.

127. Knöss W. Assessment report on *Gentiana lutea* L., Radix [online]. 2009 [cited Mar 14, 2020]. Available from: www.ema.europa.eu/en/documents/herbal-report/superseded-assessment-report-gentiana-lutea-l-radix-first-version_en.pdf

128. Zagler B, Zelger A, Salvatore C, Pechlaner C, De Giorgi F, Wiedermann CJ. Dietary poisoning with *Veratrum album*-- a report of two cases. *Wien Klin Wochenschr*. 2005; 117: 106-8.

129. Rauber-Luthy C, Halbsguth U, Kupferschmidt H, Konig N, Megevand C, Zihlmann K, et al. Low-dose exposure to *Veratrum album* in children causes mild effects-- a case series. *Clin Toxicol (Phila)*. 2010; 48: 234-7.

130. Lee MR. Ipecacuanha: the South American vomiting root. *J R Coll Physicians Edinb.* 2008; 38: 355-60.

131. Hasegawa M, Sasaki T, Sadakane K, Tabuchi M, Takeda Y, Kimura M, et al. Studies for the emetic mechanisms of ipecac syrup (TJN-119) and its active components in ferrets: involvement of 5-hydroxytryptamine receptors. *Jpn J Pharmacol.* 2002; 89: 113-9.

132. Manoguerra AS, Cobaugh DJ. Guideline on the use of ipecac syrup in the out- of- hospital management of ingested poisons. *Clin Toxicol (Phila).* 2005; 43: 1-10.

133. Hojer J, Troutman WG, Hoppu K, Erdman A, Benson BE, Megarbane B, et al. Position paper update: ipecac syrup for gastrointestinal decontamination. *Clin Toxicol (Phila).* 2013; 51: 134-9.

134. Minton N, Swift R, Lawlor C, Mant T, Henry J. Ipecacuanha-induced emesis: a human model for testing antiemetic drug activity. *Clin Pharmacol Ther* 1993; 54: 53-7.

135. Whipple FA, Woodside JM. The Analysis of Ipecac—Drug, tincture, and fluid extract. *J Am Pharm Assoc (Scientific ed).* 1948; 37: 83-6.

136. Smith RP, Smith DM. Acute Ipecac poisoning. *N Engl J Med* 1961; 265: 523-5.

137. Miser JS, Robertson WO. Ipecac poisoning. *West J Med* 1978; 128: 440-3.

138. Schiff RJ, Wurzel CL, Brunson SC, Kasloff I, Nussbaum MP, Frank SD. Death due to chronic syrup of ipecac use in a patient with bulimia. *Pediatrics.* 1986; 78: 412-6.

139. Silber TJ. Ipecac syrup abuse, morbidity, and mortality: isn't it time to repeal its over-the-counter status? *J Adolesc Health* 2005; 37: 256-60.

140. Ho PC, Dweik R, Cohen MC. Rapidly reversible cardiomyopathy associated with chronic ipecac ingestion. *Clin Cardiol.* 1998; 21: 780-3.

141. Council NR. Acute exposure guideline levels for selected airborne chemicals: Volume 6. Washington, DC: National Academies Press; 2008.

142. Singh S, Malhotra P, Jain S, Varma S. Gastroesophageal burns following domestic liquid ammonia ingestion: report of two cases. *J Assoc Physicians India.* 1999; 47: 647.

143. Agency for Toxic Substances and Disease Registry. Medical management guidelines for ammonia [online]. 2014 [cited Mar 14, 2020]. Available from: www.atsdr.cdc.gov/mmg/mmg.asp?id=7&tid=2.

144. Braissant O, McLin VA, Cudalbu C. Ammonia toxicity to the brain. *J Inherit Metab Dis.* 2013; 36: 595-612.

145. Dawson JA, Yager J. A case of abuse of syrup of ipecac resulting in death. *J Am Coll Health* 1986; 34: 280-2.